Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan
Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan
复制标题
DOI：
10.1016/j.vaccine.2019.02.034
复制
发表时间：
2019-03-28
期刊：
影响因子：
5.5
通讯作者：
Oishi, Kazunori
中科院分区：
文献类型：
--
作者：
Satoh, Hiroshi;Tanaka-Taya, Keiko;Oishi, Kazunori
在日本，口服脊髓灰质炎病毒疫苗（OPV）于2012年变更为2种灭活脊髓灰质炎病毒疫苗（IPV），即独立常规IPV（cIPV）和Sabin衍生IPV联合白喉-破伤风-无细胞百日咳疫苗（DTaP-sIPV），用于常规免疫。我们使用2011年至2015年全国疫苗可接种疾病流行病学监测（NESVPD）的数据评估了脊髓灰质炎疫苗接种覆盖率和脊髓灰质炎病毒抗体血清阳性率。在2012年引入IPV的几年前，由于担心疫苗相关的麻痹性脊髓灰质炎风险，一些家长拒绝为儿童接种OPV。因此，在年龄
In Japan, the oral poliovirus vaccine (OPV) was changed to 2 types of inactivated poliovirus vaccine (IPV), the standalone conventional IPV (cIPV) and the Sabin-derived IPV combined with diphtheria-tetanus-acellular pertussis vaccine (DTaP-sIPV), for routine immunization in 2012. We evaluated polio vaccination coverage and the seroprevalence of poliovirus antibodies using data from the National Epidemiological Surveillance of Vaccine-Preventable Diseases (NESVPD) from 2011 to 2015. Several years before the introduction of IPV in 2012, OPV administration for children was refused by some parents because of concerns about the risk of vaccine-associated paralytic poliomyelitis. Consequently, in children aged